⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of MannKind Corporation and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
MannKind Corporation
↗Westlake Village, California, USA
MannKind Corporation is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases. The company utilizes its proprietary Technosphere® dry-powder inhalation platform to deliver drugs efficiently via the lungs.
Beyond its core diabetes portfolio, which includes the rapid-acting inhaled insulin Afrezza® and the V-Go® wearable insulin-delivery device, MannKind has expanded into cardiometabolic and pulmonary diseases. Following its acquisition of scPharmaceuticals, the company now markets Furoscix®, an on-body infuser for chronic heart failure.
CLASSIFICATION
SIZE & FINANCIALS
Employees:201-500
Revenue:$200M-$250M
Founded:1991
Ownership:public
Status:operating
STOCK
Exchange:NASDAQ
Ticker:MNKD
Market Cap:$1.28B
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Inhaled therapeutics, Drug-device combination
Active Trials:0
Trial Phases:-
FDA Approvals:2
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:scPharmaceuticals
Key Partnerships:United Therapeutics (Tyvaso DPI), Biomm S.A. (Afrezza distribution)
COMPETITION
Position:Niche Player
Competitors:United Therapeutics, Sanofi, Eli Lilly, Novo Nordisk
LEADERSHIP
Key Executives:
Michael Castagna - CEO
Steven Binder - CFO
Scientific Founders:Alfred E. Mann
LINKS
Website:mnkd.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with MannKind Corporation. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.